ADHD, schizophrenia and methylphenidate
Peter Mason
The use of methylphenidate (MPH) to treat attention deficit hyperactivity disorder (ADHD) in patients with comorbid psychosis is controversial, with much evidence to suggest that stimulants can increase psychosis levels in 50–70% of patients with schizophrenia. This is not surprising when one considers the mode of action of stimulant drugs and the dopamine hypothesis of schizophrenia.
ADHD in practice 2010; 2(2): 8–10
To continue reading this article, please sign in or register.

ADHD in practice is supported by an unrestricted educational grant from MEDICE, with no editorial input into the content of this publication.

ADHD Together logo

ADHD in practice was previously supported by Shire from 2009 to 2016.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly, the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title ADHD in practice is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2019 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: editor@adhdinpractice.co.uk

ISSN 2041-2215 (Print) ISSN 2045-7766 (Online)